Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455624 · ClinicalTrials.gov registry record
Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 60
- Enrollment target
NCT00455624: Completed study, sponsored by Massachusetts General Hospital.
NCT00455624 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00455624 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if androgen deprivation therapy affects insulin, cardiac risk factors such as cholesterol level, and body fat and muscle.
Interventions
- DRUG Androgen deprivation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-11 |
| Est. Completion | 2006-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455624
The ClinicalTrials.gov registry entry for NCT00455624 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Androgen deprivation therapy is the first listed.
NCT00455624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00455624 about?
NCT00455624 is a clinical study titled "Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer". The purpose of this study is to find out if androgen deprivation therapy affects insulin, cardiac risk factors such as cholesterol level, and body fat and muscle.
What is the current status of trial NCT00455624?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2002-11. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00455624?
The interventions under investigation include: Androgen deprivation therapy (DRUG).
Who is sponsoring clinical trial NCT00455624?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.